Personalized approach to HER2-positive advanced breast cancertherapy

Abstract

Anti-HER2 therapy is a standard component of drug therapy for HER2-positive breast cancer. The advent of new drugs of this group creates additional possibilities for treatment and necessitates for creating an algorithm according to the characteristics of each patient. We analyzed possible therapeutic options concerning international guidelines for treating HER2-positive advanced breast cancer.

Keywords

• t-dm1
• advanced breast cancer
• her2-targeted therapy
• trastuzumab
• lapatinib
• pertuzumab
• t-dm1